Featured content in this Issue: Companies, organisations and drug candidates mentioned in this Bulletin include: atai Life Sciences, TARA Mind, GH Research, Cybin, Psilera, Incannex. This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.


Previous articleEnsuring the Affordable Becomes Accessible – Lessons from Ketamine’s Antidepressant Development and a Vision for More Equitable Drug Development
Next articlePT481 – Kanna: The History, Science, and Potential of an Emerging Legal Alternative